LifeVantage Corporation (LFVN)

Market Cap	79.61M -52.8%
Revenue (ttm)	182.59M -20.1%
Net Income	5.07M -48.3%
EPS	0.40 -46.7%
Shares Out	12.53M
PE Ratio	15.89
Forward PE	21.91
Dividend	$0.20 (3.15%)
Ex-Dividend Date	Sep 1, 2026

Volume	112,927
Open	6.00
Previous Close	6.45
Day's Range	5.86 - 6.63
52-Week Range	3.90 - 14.28
Beta	0.76
Analysts	Buy
Price Target	7.50 (+18.02%)
Earnings Date	Aug 27, 2026

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, ...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Terrence Moorehead
• Employees: 238
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN
• Website: https://www.lifevantage.com

Financial Performance

In fiscal year 2026, LifeVantage's revenue was $182.59 million, a decrease of -20.10% compared to the previous year's $228.53 million. Earnings were $5.07 million, a decrease of -48.27%.

Analyst Summary

According to 2 analysts, the average rating for LFVN stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 18.02% from the latest price.

Price Target

$7.5

(18.02% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 29, 2026

Data Sources Report a data error